Bietti's crystalline dystrophy: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{SI}} | |||
{{Infobox medical condition | |||
| name = Bietti's crystalline dystrophy | |||
| image = [[File:Autorecessive.svg|200px]] | |||
| caption = Bietti's crystalline dystrophy is inherited in an [[autosomal recessive]] pattern. | |||
| synonyms = Bietti crystalline corneoretinal dystrophy | |||
| field = [[Ophthalmology]] | |||
| symptoms = [[Night blindness]], [[peripheral vision]] loss, [[glare]] sensitivity | |||
| onset = [[Adulthood]] | |||
| duration = [[Chronic (medicine)|Chronic]] | |||
| causes = Mutations in the [[CYP4V2]] gene | |||
| risks = [[Genetic predisposition]] | |||
| diagnosis = [[Clinical diagnosis]], [[genetic testing]] | |||
| differential = [[Retinitis pigmentosa]], [[Stargardt disease]] | |||
| treatment = No specific treatment, [[low vision]] aids | |||
| prognosis = Progressive vision loss | |||
| frequency = Rare | |||
}} | |||
'''Bietti's Crystalline Dystrophy''' ('''BCD''') is a rare, inherited eye disorder characterized by the formation of crystal deposits in the [[cornea]] and [[retina]]. These deposits can lead to progressive vision loss and eventually blindness. The condition was first described by Italian ophthalmologist G. B. Bietti in 1937. | '''Bietti's Crystalline Dystrophy''' ('''BCD''') is a rare, inherited eye disorder characterized by the formation of crystal deposits in the [[cornea]] and [[retina]]. These deposits can lead to progressive vision loss and eventually blindness. The condition was first described by Italian ophthalmologist G. B. Bietti in 1937. | ||
==Etiology== | ==Etiology== | ||
BCD is caused by mutations in the [[CYP4V2]] gene, which is involved in the metabolism of fatty acids. The exact mechanism by which these mutations lead to the formation of crystal deposits is not fully understood. However, it is believed that the mutations disrupt the normal function of the CYP4V2 protein, leading to an accumulation of lipids in the eye. | BCD is caused by mutations in the [[CYP4V2]] gene, which is involved in the metabolism of fatty acids. The exact mechanism by which these mutations lead to the formation of crystal deposits is not fully understood. However, it is believed that the mutations disrupt the normal function of the CYP4V2 protein, leading to an accumulation of lipids in the eye. | ||
==Symptoms== | ==Symptoms== | ||
The primary symptom of BCD is the presence of yellow-white crystal deposits in the cornea and retina. These deposits can be seen during an eye examination. Other symptoms include progressive vision loss, night blindness, and a decrease in peripheral vision. In some cases, patients may also experience [[photophobia]], or sensitivity to light. | The primary symptom of BCD is the presence of yellow-white crystal deposits in the cornea and retina. These deposits can be seen during an eye examination. Other symptoms include progressive vision loss, night blindness, and a decrease in peripheral vision. In some cases, patients may also experience [[photophobia]], or sensitivity to light. | ||
==Diagnosis== | ==Diagnosis== | ||
Diagnosis of BCD is based on the presence of characteristic crystal deposits in the eye, as well as genetic testing to identify mutations in the CYP4V2 gene. Other tests, such as electroretinography and optical coherence tomography, may also be used to assess the extent of retinal damage. | Diagnosis of BCD is based on the presence of characteristic crystal deposits in the eye, as well as genetic testing to identify mutations in the CYP4V2 gene. Other tests, such as electroretinography and optical coherence tomography, may also be used to assess the extent of retinal damage. | ||
==Treatment== | ==Treatment== | ||
There is currently no cure for BCD. Treatment is focused on managing symptoms and slowing the progression of the disease. This may include the use of low-vision aids, such as magnifying glasses and large-print materials, as well as counseling and support for coping with vision loss. | There is currently no cure for BCD. Treatment is focused on managing symptoms and slowing the progression of the disease. This may include the use of low-vision aids, such as magnifying glasses and large-print materials, as well as counseling and support for coping with vision loss. | ||
==Prognosis== | ==Prognosis== | ||
The prognosis for individuals with BCD varies. Some individuals may maintain functional vision into their 50s or 60s, while others may become legally blind by their 30s or 40s. The rate of progression can vary widely, even among individuals with the same mutation. | The prognosis for individuals with BCD varies. Some individuals may maintain functional vision into their 50s or 60s, while others may become legally blind by their 30s or 40s. The rate of progression can vary widely, even among individuals with the same mutation. | ||
==See also== | ==See also== | ||
* [[Retinal diseases]] | * [[Retinal diseases]] | ||
* [[Genetic disorders]] | * [[Genetic disorders]] | ||
* [[Ophthalmology]] | * [[Ophthalmology]] | ||
==References== | ==References== | ||
<references /> | <references /> | ||
[[Category:Eye diseases]] | [[Category:Eye diseases]] | ||
[[Category:Genetic disorders]] | [[Category:Genetic disorders]] | ||
| Line 34: | Line 39: | ||
{{Eye-disease-stub}} | {{Eye-disease-stub}} | ||
{{Genetics-stub}} | {{Genetics-stub}} | ||
Latest revision as of 19:11, 4 April 2025
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss NYC and sleep center NYC
| Bietti's crystalline dystrophy | |
|---|---|
| |
| Synonyms | Bietti crystalline corneoretinal dystrophy |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Night blindness, peripheral vision loss, glare sensitivity |
| Complications | N/A |
| Onset | Adulthood |
| Duration | Chronic |
| Types | N/A |
| Causes | Mutations in the CYP4V2 gene |
| Risks | Genetic predisposition |
| Diagnosis | Clinical diagnosis, genetic testing |
| Differential diagnosis | Retinitis pigmentosa, Stargardt disease |
| Prevention | N/A |
| Treatment | No specific treatment, low vision aids |
| Medication | N/A |
| Prognosis | Progressive vision loss |
| Frequency | Rare |
| Deaths | N/A |
Bietti's Crystalline Dystrophy (BCD) is a rare, inherited eye disorder characterized by the formation of crystal deposits in the cornea and retina. These deposits can lead to progressive vision loss and eventually blindness. The condition was first described by Italian ophthalmologist G. B. Bietti in 1937.
Etiology[edit]
BCD is caused by mutations in the CYP4V2 gene, which is involved in the metabolism of fatty acids. The exact mechanism by which these mutations lead to the formation of crystal deposits is not fully understood. However, it is believed that the mutations disrupt the normal function of the CYP4V2 protein, leading to an accumulation of lipids in the eye.
Symptoms[edit]
The primary symptom of BCD is the presence of yellow-white crystal deposits in the cornea and retina. These deposits can be seen during an eye examination. Other symptoms include progressive vision loss, night blindness, and a decrease in peripheral vision. In some cases, patients may also experience photophobia, or sensitivity to light.
Diagnosis[edit]
Diagnosis of BCD is based on the presence of characteristic crystal deposits in the eye, as well as genetic testing to identify mutations in the CYP4V2 gene. Other tests, such as electroretinography and optical coherence tomography, may also be used to assess the extent of retinal damage.
Treatment[edit]
There is currently no cure for BCD. Treatment is focused on managing symptoms and slowing the progression of the disease. This may include the use of low-vision aids, such as magnifying glasses and large-print materials, as well as counseling and support for coping with vision loss.
Prognosis[edit]
The prognosis for individuals with BCD varies. Some individuals may maintain functional vision into their 50s or 60s, while others may become legally blind by their 30s or 40s. The rate of progression can vary widely, even among individuals with the same mutation.
See also[edit]
References[edit]
<references />
